Home » Newsletters » BioWorld Science

BioWorld Science

March 23, 1999

View Archived Issues

Collaboration between Wyeth and Aviron for FluMist effective immediately

Ergo Science intends to appeal FDA decision on Ergoset

Study data on Periodontix's gingivitis treatment reported

Piperazine derivatives for lower urinary tract disorders designed at Recordati

Japan is country of first launch for Yamanouchi's second-generation t-PA

AMPA receptor antagonists claimed for epilepsy, muscle spasms and neurodegenerative disorders

New formulation of buspirone shows improved pharmacokinetics, not affected by hepatic impairment

Novel acridine-based antitumor agents developed at Italian university

Nonemetic PDE4 inhibitors in development at Almirall Prodesfarma

Merck's new GABA-A inverse agonists for cognition disorders

DuPont presents potent and selective factor Xa inhibitors

ACS highlights: new noncovalent thrombin inhibitors described by Merck & Co.

SD/01, a pegylated form of filgrastim with superior pharmacokinetics

SBIR grant to be used by Aurora to identify gene targets, lead compounds relevant to breast cancer

New dosage strength and expanded indications approved for Climara

Positive phase I results reported for Il Yang's proton pump inhibitor

ABT-627 now being evaluated in humans

SB-247083: design of a selective, orally active ETA antagonist

New patent expands protection for BioTransplant's AlloMune and XenoMune systems

SLV-307, a compound with dual dopaminergic and serotonergic effects in humans

Connetics launches Luxiq at Dermatology Conference

New thioureas: synthesis and apoptosis induction

Lilly reports initial clinical data for LY-333531

ACS highlights: design of new antitumor agents based on computer models of tubulin structure

Calpain I inhibitors designed at Cephalon show neuroprotective activity in animal model

Romozin cannot be reintroduced in the U.K., MCA says

Another anticoagulant series presented by DuPont at the ACS meeting

NCI scientists evaluate MMP inhibitor from CollaGenex

Merck's faster acting and more potent formulation relieves headache pain better than ibuprofen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...